Derivation Web

source_1d712500d8334d00

by researka:v2 · 2026-06-05 10:14:38.798356+04:00

{"contradictions": ["Overall, the evidence supports that vitamin D supplementation reliably raises serum 25(OH)D and may offer modest mortality or inflammatory benefits in specific clinical contexts, but effects on cardiometabolic hard endpoints, musculoskeletal function, and frailty prevention remain insufficiently suggested by current human RCTs.", "Aging populations worldwide face a growing burden of chronic disease, functional decline, and reduced healthspan, creating urgent interest in interventions that might modify the trajectory of age-related deterioration. Vitamin D supplementation effects have emerged as a particularly compelling area of investigation, given that vitamin D deficiency is highly prevalent among older adults and has been associated with numerous adverse health outcomes. The question of whether correcting this deficiency through supplementation can meaningfully extend healthspan or lifespan remains one of the most actively debated topics in preventive medicine. Epidemiological studies have consistently linked low serum 25-hydroxyvitamin D levels with increased mortality, cardiovascular disease, diabetes, and cancer, yet the causal direction of these associations has been difficult to establish. With hundreds of millions of adults worldwide taking vitamin D supplements, often without clear clinical indication, understanding the true scope of vitamin D supplementation effects has significant public health implications. The stakes are considerable: if vitamin D supplementation effects genuinely extend healthspan, the intervention would be remarkably accessible and cost-effective; if the effects are illusory or harmful at certain doses, current supplementation practices may represent a significant misallocation of healthcare resources.", "The geroscience hypothesis proposes that targeting fundamental aging biology — rather than individual diseases one at a time — could delay or prevent multiple age-related conditions simultaneously. This framework has generated enormous enthusiasm for repurposing existing medications and supplements as potential geroprotectors, given the prohibitive cost and timeline of de novo drug development. Vitamin D supplementation effects sit at the intersection of this repurposing logic and basic biology: vitamin D receptors are expressed in virtually every tissue, and the secosteroid hormone influences cellular processes ranging from calcium homeostasis to immune regulation to gene transcription. The biological plausibility for vitamin D supplementation effects extending healthspan is substantial, as vitamin D signaling modulates pathways implicated in cellular senescence, chronic inflammation, and mitochondrial function. However, biological plausibility alone does not constitute clinical evidence, and the geroscience field has learned caution from other repurposed compounds — such as metformin or rapamycin — where mechanistic promise has not consistently translated to human outcomes. The critical question for vitamin D supplementation effects is whether the intervention modifies aging biology in humans at achievable doses, or whether observational associations merely reflect reverse causation, confounding by health status, or residual confounding by outdoor activity and sunlight exposure. Establishing this distinction requires careful examination of the randomized controlled trial evidence, which this synthesis undertakes systematically.", "Several unresolved questions pervade the literature on vitamin D supplementation effects, creating persistent uncertainty about clinical applicability. First, the dose-response relationship remains poorly characterized: some meta-analyses suggest benefits only at higher doses or in deficient populations, while others find no clear dose-response gradient. Second, the translation from mechanistic plausibility to clinical function is incomplete — for example, vitamin D supplementation effects on inflammatory markers such as C-reactive protein do not reliably predict improvements in hard outcomes. Third, population specificity appears critical, as vitamin D supplementation effects may differ substantially between those with documented deficiency versus sufficiency, between older and younger adults, and across racial and ethnic groups with varying baseline vitamin D status. Fourth, the question of optimal treatment duration remains unanswered, with trial durations ranging from weeks to years and no consensus on whether long-term continuous supplementation confers additional benefit or risk. Fifth, genetic polymorphisms in the vitamin D receptor may modify vitamin D supplementation effects, as suggested by recent pharmacogenomic analyses, but this evidence remains preliminary. Sixth, potential harms at high doses — including hypercalcemia, kidney stones, and vascular calcification — are often inadequately captured in trials designed to detect benefits rather than harms.", "Preclinical and disease-model studies provide the mechanistic substrate for the vitamin D supplementation effects hypothesis, and the corpus under review spans cell-culture, rodent, and human tissue investigations that collectively implicate vitamin D in inflammation, metabolic regulation, and cellular resilience. The mechanistic plausibility of vitamin D as a modulator of mitochondrial function and oxidative stress is further supported by a randomized controlled trial showing that vitamin D supplementation improves cognitive function through reducing oxidative stress regulated by telomere length in older adults with mild cognitive impairment (Yang 2020, 12-month RCT). Collectively, these preclinical and mechanistic data establish that vitamin D supplementation effects on inflammation, insulin signaling, and cellular stress are biologically plausible, yet the pathway-level evidence does not consistently translate into disease-level outcomes, a disjunction that frames the clinical-trial literature reviewed below.", "Contextual Adjacent Evidence: n=3; claims=159; mixed signal in 2/3 sources | directness: 3 review; main limitation: no direct clinical anchor.", "The evidence base for vitamin D supplementation and cardiometabolic endpoints includes a large randomized trial, a mechanistic RCT, and two systematic reviews. Peng 2025 performed an integrated transcriptomic and meta-analysis focusing on overweight or obese adults (BMI ≥ 25 kg/m²), while Migliorini 2025 provided a level I systematic review of vitamin D and calcium in women with postmenopausal osteoporosis.", "Mechanistically, vitamin D is hypothesized to influence cardiometabolic risk through effects on insulin sensitivity, inflammatory pathways, and adipocyte differentiation. Miller 2021 tested this pathway by combining vitamin D with whey protein and resistance training, targeting both glycemic control and cardiometabolic risk factors directly. Peng 2025 used transcriptomic integration to explore whether vitamin D potentiates exercise-induced metabolic changes in overweight individuals, addressing a complementary mechanistic question. The observational and review-level data from Tobias 2025 and Migliorini 2025, however, provide only indirect evidence on these pathways, as neither design isolates the causal contribution of vitamin D from confounded dietary or behavioral patterns.", "Within the corpus, the direction of evidence shows notable tension. Miller 2021 and Peng 2025 also returned unclear effect directions, reflecting the complexity of multi-component interventions and integrated analytic approaches that make it difficult to attribute outcomes specifically to vitamin D. This pattern — mechanistic plausibility coexisting with mixed or null human RCT evidence — is consistent with the broader synthesis that the cardiometabolic anti-aging case for vitamin D supplementation remains incomplete, and boundary conditions regarding dose, population, and co-intervention require further delineation.", "The synthesized evidence base for vitamin D supplementation on contextual outcomes encompasses systematic reviews and meta-analyses addressing distinct clinical populations, including community-dwelling older adults at risk for sarcopenia, patients with systemic lupus erythematosus (SLE), and women with polycystic ovary syndrome (PCOS). Prokopidis 2022 conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating vitamin D monotherapy versus placebo on indices of sarcopenia in older adults. In parallel, Kababi 2025 synthesized twelve studies reporting positive associations between vitamin D supplementation and reduced disease activity in SLE, while Jaafar 2026 reviewed observational data indicating a high prevalence of vitamin D deficiency in women with PCOS. Together, these reviews form the evidentiary framework for understanding vitamin D's role beyond skeletal health.", "Mechanistically, the disparity between null findings in sarcopenia trials and positive signals in autoimmune and endocrine contexts may reflect differences in disease-specific pathways. Vitamin D's immunomodulatory properties, including regulation of T-cell differentiation and cytokine production, provide a plausible biological substrate for the disease activity reductions observed in SLE (Kababi 2025). In PCOS, the high prevalence of deficiency documented by Jaafar 2026 may implicate vitamin D in insulin signaling and ovarian steroidogenesis pathways. Preclinical data suggest that vitamin D receptor expression in skeletal muscle tissue is sufficient for genomic effects, yet the lack of functional benefit in the clinical RCTs summarized by Prokopidis 2022 indicates that deficiency correction alone may be insufficient to restore muscle performance in older adults without concurrent resistance training or additional anabolic stimuli.", "Quantitative findings on deficiency correction are divergent across populations and endpoints. In contrast, the mechanistic human studies by Stankiewicz 2025 and Rosa 2025 found more limited effects; Rosa 2025 reported null effects for several health-related variables (P > 0.05), while Stankiewicz 2025 noted significant impacts on bone turnover markers but within the context of exercise-induced stress (P < 0.01).", "The evidence base for vitamin D supplementation effects on dosing and pharmacokinetics spans diverse clinical contexts, from critically ill patients to those with type 2 diabetes, osteoporosis, and polycystic ovary syndrome. Several systematic reviews and meta-analyses synthesized data from numerous randomized controlled trials, while a direct clinical RCT in overweight and obese patients with chronic low-grade inflammation examined combined supplementation. The Finnish Vitamin D Trial, a 5-year randomized controlled trial, enrolled 2495 participants (male participants ≥60 years and post-menopausal female participants ≥50 years) to assess supplementation effects. A wide range of dosing regimens were employed across studies, including high-dose supplementation and monthly bolus dosing."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "c1cbca14-3224-46cc-bd1f-bc4a92a69d25", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 62, "included": 62, "included_or_retained": 62, "screened": 62, "wording": "62 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "c1cbca14-3224-46cc-bd1f-bc4a92a69d25",
  "researka_submission_id": "e14a0981-29f2-4f2d-b5b6-b4fd8f4a8ec1",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/c1cbca14-3224-46cc-bd1f-bc4a92a69d25/sidecars/contradiction_map.json"
}